Quarterly report pursuant to Section 13 or 15(d)

BUSINESS COMBINATIONS AND ASSET PURCHASES - Schedule of pro forma information (Details)

v3.23.1
BUSINESS COMBINATIONS AND ASSET PURCHASES - Schedule of pro forma information (Details) - Kind Therapeutics USA LLC.
12 Months Ended
Dec. 31, 2022
USD ($)
Business Acquisition [Line Items]  
Revenue $ 136,078,000
Net income $ 15,823,000